Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Only 26K shares short ....as of Monday 14th....

<< Previous

Bullboard Posts

Next >>

Comment by MasterAlgaeon Dec 21, 2020 11:25am

90 Views

Post# 32152691

RE:RE:RE:RE:RE:RE:Only 26K shares short ....as of Monday 14th....

It would be nice to have transparency in regards to the short positions.

It could be easily tracked in real time in the 21st century, you'd almost think that the opaqueness was a deliberate advantage over the majority of investors...

<< Previous

Bullboard Posts

Next >>

Canadian government to fund Electric Royalties portfolio property